the daytime, the protective activity against methacholine during the 12 hours of the Background -Previous studies evaluating monitoring period being constant. Furspirometric values and symptoms have thermore there was no difference in the shown that once daily theophylline admean FEV 1 between the two treatments at ministered in the evening produces greater 14.00 and 20.00 hours. stabilisation of the airway function in asthConclusions -In adults with stable bronmatic patients than the prototype theochial asthma treatment with a single dose phylline given twice a day. The aim of of Diffumal-24 administered in the eventhis study was to compare the effects on ing improved airflow obstruction and rebronchial responsiveness to methacholine duced bronchial hyperresponsiveness. of an ultrasustained release theophylline (Thorax 1997;52:969-974) formulation (Diffumal-24, Malesci, Florence, Italy) administered once a day, a Keywords: theophylline, bronchial hyperresponsivesustained release theophylline formulation ness, bronchial asthma. (Theo-Dur, Recordati, Milan, Italy) administered twice a day, and placebo. Methods -The study was performed in 12 Oral theophylline formulations are widely used adult patients with asthma using a ran-in the treatment of bronchial asthma. During domised, double blind, three phase, cross-the past 10 years increased knowledge of the over design. Each phase lasted seven days pharmacokinetics, availability of theophylline and was followed or preceded by at least assays, and the development of sustained rethree days of theophylline washout. Diffu-lease formulations have led to a safer and more mal-24 was administered once a day at effective use of the drug.
Diffumal-24 is an ultrasustained release theo-
used to allow the study to be blind. administered as a single dose of Diffumal-24 at 08.00 hours or divided into two doses of Theo-Dur at 08.00 and 20.00 hours.
The study was of a double blind, crossover, Previous studies evaluating spirometric values and symptoms have shown that once a placebo controlled design. Patients were assigned to treatments according to a 3×3 latin day theophylline administered in the evening produced greater stabilisation of airway func-square design and received orally for seven days, in three separate periods, either placebo, tion than the prototype theophylline formulation given twice a day to asthmatic once daily sustained release theophylline, or the same dosage of twice daily sustained release patients. 10 11 In recent years emphasis on bronchial hyperresponsiveness as an important theophylline. The placebo and both once daily and twice daily theophylline formulations were feature of asthma has become generally accepted. 12 13 We have therefore compared the contained in identical wafers. The procedure was as follows: (1) two wafers containing effects on bronchial hyperresponsiveness in adult patients with asthma of once a day theo-placebo in the morning and two in the evening;
(2) two wafers containing Theo-Dur at 08.00 phylline administered in the evening with that of a reference theophylline formulation given hours and two at 20.00 hours; (3) two wafers containing placebo at 08.00 hours and two twice a day.
wafers containing Diffumal-24 at 20.00 hours. The three treatment periods were separated by a washout period of at least three days.
Methods


Inhaled agonists were continued throughout the trial and patients were asked to keep Twelve non-smoking asthmatic subjects (eight men) of mean age 41.5 years (range 23-62) the daily dosage of these medications constant until the seventh day of each treatment period took part in the study (table 1) . The diagnosis had been established using the criteria defined at which time they were withheld for 12 hours before performing spirometric tests and the by the American Thoracic Society.
14 Respiratory symptoms were well controlled by ad-methacholine challenge. Drugs known to affect theophylline metabolism were withdrawn three ministration of theophylline or inhaled agonists which were part of their therapeutic weeks before the onset of the study and were not allowed during the trial. The patients were regimen. Treatment with drugs affecting bronchial responsiveness such as steroids or inhaled asked to refrain from coffee and tea and from any medication containing xanthines (except cromolyn had been suspended during the month before the beginning of the study if the the study drugs as specified). On the seventh day of each treatment period the patients patient had been taking them previously. Eight had a positive skin test reaction to aeroallergens underwent spirometric tests and bronchial challenge with methacholine at 08.00, 14.00, but were not exposed to the relevant allergens during the study. Pregnant patients or nursing and 20.00 hours At these times blood samples were taken for theophylline analysis. mothers were excluded as were patients with clinically significant cardiac, renal, hepatic or metabolic disease. All subjects had proven airway hyperresponsiveness -that is, a 20% de-     crease in forced expiratory volume in one second (FEV 1 ) with Ζ1500 g methacholine Forced expiratory volume in one second (FEV 1 ) was measured using a water sealed (the method of methacholine challenge is described below). Basal FEV 1 values were above spirometer (Biomedin, Padua, Italy) and the bronchial challenge with methacholine was car-70% of the predicted value 15 for all subjects. Patients gave written informed consent prior ried out using an ampoule dosimeter device (Mefar, Brescia, Italy). The dosimeter was to participation in the study.
triggered by an inspiration activated solenoid valve which remained open for one second to allow the generation of an aerosol with pres-    The test medications were Theo-Dur (200 mg, sured air of 1.5 kg/cm 2 . Two solutions of methacholine (Sigma Chemie, 0.1% and 1.0%, twice daily sustained release theophylline tablets; Recordati Spa, Milan, Italy) and Diffumal-respectively) in a phosphate buffer were prepared daily. After an initial inhalation of phos-24 (200 mg, once daily sustained release theophylline tablets; Malesci Spa, Florence, Italy). phate buffer only, methacholine was inhaled by group.bmj.com on September 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from the subjects in doses ranging from 20 g to a total cumulative dose of 2000 g. The dose was increased by changing the methacholine concentration and/or the number of breaths. FEV 1 was determined immediately before the challenges, after inhalation of the buffer, and after each inhalation of methacholine. The methacholine test was ended when FEV 1 fell more than 20% compared with the value measured after the buffer challenge. The results of the bronchial challenge were expressed by the dosage of methacholine causing a 20% fall of FEV 1 (PD 20 ). We calculated this datum by interpolating in the semilogarithmic dose-response curve, the point corresponding to the dose causing the fall in FEV 1 just below 20% and 20.00 hours on the seventh day of each treatment period. Samples were coded so the technician did not know which preparation was represented by any given sample. Serum theophylline concentrations were assayed in Serum theophylline concentrations were undeterminable during the placebo treatment duplicate by means of a homogenous enzyme immunoassay (Emit, Syva Inc, Palo Alto, Cali-period in all the patients. Diffumal-24 produced a significantly higher serum theophylline fornia, USA). The coefficient of variation for theophylline assay was 4.9%. From the serum concentration than Theo-Dur at 08.00 hours (16.6 (1.1) versus 10.1 (0.6) mg/l, p<0.001). theophylline concentrations over time, the area under the curves (AUC) was calculated by However, at 20.00 hours serum theophylline levels after Theo-Dur (10.8 (1.0) mg/l) were linear trapezoidal rule.
higher than those seen after Diffumal-24 (8.3 (0.7) mg/l, p<0.01). No difference in theophylline concentration between the two drugs was found at 14.00 hours (Theo-Dur, 12.3   The data are expressed as mean (SE) values. (1.0) mg/l; Diffumal-24, 11.2 (0.9) mg/l).
Within-drug comparison revealed that during Analysis of variance (ANOVA) for repeated measures was first performed to assess the the Diffumal-24 treatment period the mean serum theophylline concentrations at 08.00, relevance of various factors (treatment, time of sample collection, and treatment by time 14.00, and 20.00 hours were significantly different from one another (p<0.01). During interaction) in explaining the observed changes in FEV 1 , PD 20 and theophylline serum levels. Theo-Dur dosing there was no difference between the mean concentrations of theophylline PD 20 values were log transformed (natural logarithm, lnPD 20 ) before the analysis. If the inter-measured at 08.00 hours and 20.00 hours, but at 14.00 hours the mean concentration was action term was statistically significant -that is, the relative effects of treatments varied mark-significantly higher.
The relative bioavailabilities of theophylline edly at different sample times -thus leading to incorrect estimates of treatment and time measured over the 12 hour period were similar with both therapeutic regimens, the Theo-Dur effects, separate analysis by treatment and by time was performed. A Duncan test for multiple to Diffumal-24 ratio of the area under the concentration-time curve being 0.96. comparisons was used to assess the grouping of treatments and times when the corresponding At 08.00 hours one patient had a serum theophylline concentration below 8 mg/l ANOVA F test was significant at the specified alpha level. 20 measured at 08.00 14.00 hours and 20.00 hours. When the hours was significantly lower than that obtained patients with theophylline serum levels below at 20.00 hours (p<0.01) whereas no difference 8 mg/l were withdrawn from the analysis the was found between the values recorded at any difference between the effect of Diffumal-24 other time.
and Theo-Dur on methacholine induced With Theo-Dur the lnPD 20 was increased, bronchoconstriction at 08.00 hours was still though not significantly (5.18 (0.31) at 08.00 significant.
Diffumal-24 stabilised the bronchial response to methacholine so that there was no ences at each time between treatments with 95% CI are reported. The interaction term nificantly lower than at 14.00 hours (3.1 (0.3) l;
group.bmj.com on September 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from p<0.01). During the Theo-Dur treatment contrary, it is of critical importance to produce the maximum serum theophylline conperiod there were no significant differences between FEV 1 at 08.00 hours (3.0 (0.2) l), centrations in the early morning which is the time when bronchial hyperresponsiveness is 14.00 hours (3.1 (0.2) l), and 20.00 hours (3.0 (0.2) l). The once a day formulation of highest.
Our study therefore adds a further piece of theophylline produced significantly greater bronchodilation than placebo at 08.00 hours evidence in favour of the concept that optimal control of asthma requires that maximum con-(p<0.01) whereas the twice a day formulation did not. No significant difference was found in centrations of theophylline are achieved at the time of the patient's greatest need for airway FEV 1 between treatments at 14.00 hours and 20.00 hours protection 11 rather than minimisation of fluctuation in serum levels of the drug. 21 22 After evening administration of the once a day formulation there was a significant increase Discussion During placebo administration the lowest mean in FEV 1 values in the morning compared with placebo which did not occur after Theo-Dur. values of PD 20 were found at 08.00 hours with a progressive increase in the parameter at 14.00 However, no difference between the effect of the two theophylline products was found at and 20.00 hours, consistent with previous reports of diurnal variation in airway 14.00 and 20.00 hours. These findings confirm previous studies showing that once daily theoresponsiveness. 9 16 Despite the substantial morning fall in PD 20 there was no significant phylline therapy is as effective or more so than twice daily therapy for controlling asthma 23-28 in daytime variation in FEV 1 . These data support the hypothesis that the increase in bronchial patients with severe 11 or moderately severe 10 28
airflow limitation. They also show that the responsiveness is not dependent on, or need not result in, airflow obstruction. 17 drug has a similar benefit in patients with mild bronchial obstruction. The administration of the once daily theophylline formulation at 20.00 hours produced
After treatment with the once a day theophylline formulation only one subject had theoa decrease in the morning sensitivity to methacholine that was significantly greater than that phylline serum levels above 20 mg/l in the morning. We cannot exclude that serum conseen after the twice daily regimen. The better protective effect of Diffumal-24 compared with centrations above the therapeutic range might have occurred in other patients during the Theo-Dur may be due to the higher serum theophylline concentrations obtained at 08.00 night, even though none complained of clinically relevant adverse effects. This point must hours and suggests a dose-related effect of theophylline on bronchial hyperresponsive-be carefully considered when the total dose of theophylline is administered in the evening. ness. [18] [19] [20] Another explanation for the better protective effect against methacholine seen with
The design of our study did not enable us to check for carry over effects of treatment. Diffumal-24 might be the higher mean FEV 1 values registered at 08.00 hours after ad-However, carry over effects are unlikely since a washout period of at least three days (which ministration of the once daily theophylline (see below). However, the difference between FEV 1 in many patients lasted for 4-6 days) seems adequate to eliminate theophylline completely value at 08.00 hours after Theo-Dur and Diffumal-24 was slight and not statistically sig-in patients without cardiac or hepatic disease.
In conclusion, our results have shown that a nificant so an alternative hypothesis, such as an effect of theophylline on bronchial re-once a day theophylline formulation taken in the evening compared with a twice a day forsponsiveness not dependent on its bronchodilating activity, cannot be excluded. mulation results in a higher serum theophylline concentration in the morning when maximum The morning advantage of this particular once a day theophylline formulation -that is, airway narrowing and hyperresponsiveness occur. This improves bronchial obstruction and the greater effect on airways at 08.00 hours in comparison with the conventional twice daily significantly reduces sensitivity to methacholine in the morning without a deterioration in the theophylline treatment -was not associated with a deterioration in the state of the airway state of the airways during the daytime. Although it is tempting to speculate that the during the day; the protective activity against methacholine of Diffumal-24 and Theo-Dur at clinical use of a theophylline ultrasustained release formulation is justified by its efficacy 14.00 hours and 20.00 hours was not significantly different even if higher theophylline in decreasing bronchial hyperresponsiveness as well as its established bronchodilator effectserum levels were attained at 20.00 hours with the twice a day formulation. Furthermore, even iveness, 1 long term studies are necessary to support this hypothesis definitively. Moreover, though the fluctuation in serum theophylline concentration was considerably greater during further investigations are needed to clarify whether the results obtained in our patients treatment with the once a day theophylline formulation, the variability over 24 hours in might be applied to subjects with more severe disease and/or with more severe bronchial PD 20 was far less, indicating a greater stability of bronchial hyperresponsiveness with the evening hyperresponsiveness. administration of the once daily theophylline formulation. These findings indicate that, when 
